Latest Advances in Lung Cancer Research

New pill sevabertinib (Hyrnuo) shrinks tumors in 70% of patients with rare HER2-mutated lung cancer. Learn about this FDA fast-tracked breakthrough.

Severe viral infections, such as COVID-19, can increase the risk of lung cancer through immune cell changes, though vaccination significantly reduces these long-term harmful effects.

Dr. Ross Camidge shares clinical insights and personal reflections on the evolution of lung cancer research and the vital importance of innovation in targeted therapies.

Small cell lung cancer (SCLC) is one of the deadliest forms of lung cancer. It makes up about 15% of all lung cancer cases and has a 5-year survival rate of only 7%. While newer treatments like immunotherapy have helped some patients, most still see only small benefits. New small cell lung cancer research published in Nature Communications may help change that.

Lung cancer kills more people than breast, colon, and cervical cancers combined. Yet it is the cancer we screen for the least. A new study in the Journal of the American Medical Association shows that universal lung cancer screening could change this.

Mayo Clinic researchers found genetic and cellular clues, including missing a gene and “zombie cells”, that help explain why some lung tumors respond well to immunotherapy.

The FDA has fully approved the drug tarlatamab (Imdelltra) for small-cell lung cancer, after a trial showed it reduces death risk by ~40% compared with chemo.

A new NYT report shows that only a small fraction of people who qualify for lung-cancer screening get tested, leaving many early cancers undetected.

A Forbes article warns that few eligible Americans get lung cancer screening the and cancellation of a USPSTF meeting could delay important updates, worsening underuse.

A new Phase 3 trial finds Ivonescimab paired with chemotherapy delayed lung cancer progression by 40 % compared to a PD-1 inhibitor combo.

A new study finds that people who worked at the World Trade Center (WTC) after 9/11 and had heavy dust exposure were nearly three times more likely to develop lung cancer.

French study finds chemotherapy after lung cancer surgery shows unclear benefits for patients over 75, requiring careful patient selection.